Keay Nakae
Stock Analyst at Chardan Capital
(3.74)
# 706
Out of 4,685 analysts
195
Total ratings
34.07%
Success rate
14%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $22.30 | +169.06% | 16 | Nov 27, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $4.5 → $5 | $3.63 | +37.74% | 11 | Nov 20, 2024 | |
| ALUR Allurion Technologies | Downgrades: Neutral | n/a | $0.36 | - | 4 | Nov 14, 2024 | |
| SLN Silence Therapeutics | Maintains: Buy | $55 | $8.15 | +574.85% | 9 | Nov 14, 2024 | |
| MCRB Seres Therapeutics | Maintains: Buy | $1.25 | $0.81 | +53.43% | 8 | Nov 13, 2024 | |
| FEMY Femasys | Maintains: Buy | $10 → $8 | $1.10 | +627.27% | 10 | Nov 13, 2024 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.96 | +303.23% | 7 | Nov 13, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $50 | $27.74 | +80.25% | 7 | Nov 13, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $65 | $36.88 | +76.25% | 12 | Nov 13, 2024 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $5.98 | +134.11% | 14 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 | $2.97 | +741.75% | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 | $251.81 | +19.14% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 | $1.71 | +13,935.09% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.71 | +250.88% | 6 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.90 | +566.67% | 6 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $2.59 | +93.05% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 | $3.54 | -29.38% | 12 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.41 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $11.00 | -45.45% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $20 | $0.65 | +2,991.19% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $9.15 | +501.09% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $22.95 | -56.43% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $24.54 | +256.56% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $0.87 | +1,397.18% | 3 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $155 → $40 | $2.30 | +1,639.13% | 2 | Jun 30, 2020 |
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Buy
Price Target: $60
Current: $22.30
Upside: +169.06%
Arbutus Biopharma
Nov 20, 2024
Maintains: Buy
Price Target: $4.5 → $5
Current: $3.63
Upside: +37.74%
Allurion Technologies
Nov 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.36
Upside: -
Silence Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $55
Current: $8.15
Upside: +574.85%
Seres Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $1.25
Current: $0.81
Upside: +53.43%
Femasys
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.10
Upside: +627.27%
Orchestra BioMed Holdings
Nov 13, 2024
Maintains: Buy
Price Target: $20
Current: $4.96
Upside: +303.23%
Dyne Therapeutics
Nov 13, 2024
Maintains: Buy
Price Target: $50
Current: $27.74
Upside: +80.25%
Avidity Biosciences
Nov 13, 2024
Maintains: Buy
Price Target: $65
Current: $36.88
Upside: +76.25%
Coya Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $14
Current: $5.98
Upside: +134.11%
Nov 7, 2024
Maintains: Buy
Price Target: $25
Current: $2.97
Upside: +741.75%
Nov 1, 2024
Maintains: Buy
Price Target: $300
Current: $251.81
Upside: +19.14%
Aug 23, 2024
Maintains: Buy
Price Target: $240
Current: $1.71
Upside: +13,935.09%
Aug 9, 2024
Maintains: Buy
Price Target: $6
Current: $1.71
Upside: +250.88%
Aug 7, 2024
Maintains: Buy
Price Target: $7 → $6
Current: $0.90
Upside: +566.67%
Jun 3, 2024
Maintains: Buy
Price Target: $5
Current: $2.59
Upside: +93.05%
May 10, 2024
Maintains: Buy
Price Target: $2.5
Current: $3.54
Upside: -29.38%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.41
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $11.00
Upside: -45.45%
Nov 10, 2022
Maintains: Buy
Price Target: $60 → $20
Current: $0.65
Upside: +2,991.19%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $9.15
Upside: +501.09%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $22.95
Upside: -56.43%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $24.54
Upside: +256.56%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $0.87
Upside: +1,397.18%
Jun 30, 2020
Downgrades: Neutral
Price Target: $155 → $40
Current: $2.30
Upside: +1,639.13%